Business Context and Reporting Period
Company: Check-Cap Ltd. (Note: Input metadata referenced "Mbody AI Ltd.", but the filing text identifies the registrant as Check-Cap Ltd.)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2014
Business Overview: Check-Cap is a clinical-stage medical diagnostics company developing an ingestible imaging capsule utilizing low-dose X-rays for colorectal cancer (CRC) screening. The device is designed to be swallowed without bowel cleansing or fasting. As of the reporting date, the company had no commercial revenue and was focused on research and development (R&D), clinical trials, and regulatory approvals (FDA and CE marking).
Key Financial Metrics
| Metric (US$ in thousands) | 2014 | 2013 | 2012 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Research & Development Expenses (Net) | $3,108 | $2,662 | $2,692 |
| General & Administrative Expenses | $1,702 | $1,090 | $1,203 |
| Operating Loss | $(4,810) | $(3,742) | $(3,908) |
| Net Loss | $(4,076) | $(3,995) | $(3,721) |
| Cash and Cash Equivalents (Year End) | $1,075 | $4,975 | $4,583 |
| Working Capital | $3,214 | $4,131 | $7,451 |
| Total Shareholders' Equity | $2,227 | $1,191 | $5,129 |
| Accumulated Deficit | $(26.6 million) | Not specified | Not specified |
Note: Financial statements are prepared in accordance with International Financial Reporting Standards (IFRS). All figures are presented on a post-reverse stock split basis (1-for-20 split effective prior to the February 2015 IPO).
Material Changes vs. Prior Period
- Increased Operating Loss: The operating loss widened by 28.5% to $4.81 million in 2014 compared to $3.74 million in 2013. This was driven by a 16.8% increase in R&D expenses (due to higher salaries, subcontractor costs, and share-based payments) and a 56.1% increase in G&A expenses (primarily due to costs associated with the initial public offering).
- Net Loss Stability: Despite the higher operating loss, the net loss remained relatively flat at $4.08 million in 2014 compared to $4.00 million in 2013. This was due to a significant increase in finance income ($788k in 2014 vs. $63k in 2013), largely attributed to fair value changes on warrants and changes in royalty provisions.
- Cash Position: Cash and cash equivalents decreased significantly from $4.98 million in 2013 to $1.08 million in 2014, reflecting the cash burn from operations ($4.54 million used in operating activities).
- Equity Increase: Total shareholders' equity increased to $2.23 million in 2014 from $1.19 million in 2013, despite the net loss, due to capital stock increases.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
- Commercialization Timeline: The company anticipates launching commercially in Europe in 2016 (subject to CE marking) and in the United States in 2017 (subject to FDA approval).
- Regulatory Strategy: Plans to submit a direct de novo reclassification petition to the FDA. A pivotal study in the U.S. is expected to follow a pre-submission meeting in late 2015.
- Liquidity: Management believes existing cash resources combined with net proceeds from the February 2015 IPO and concurrent private placement (totaling approx. $22.8 million gross) will fund operations through the end of 2016.
Key Risks
- Regulatory Approval: Failure to obtain FDA clearance (510(k) or de novo) or CE marking would prevent commercialization. The device may be classified as a drug-device combination, complicating the review process.
- Capital Requirements: The company has a history of losses and expects to incur losses for the foreseeable future. Additional financing will be required beyond 2016.
- Manufacturing and Supply Chain: Reliance on single-source suppliers for critical components (motors, X-ray detectors, ASICs) poses a risk to scaling production.
- Geopolitical Risk: All operations and employees are located in Israel, exposing the company to regional political and military instability.
- Reimbursement: Success depends on third-party payors (Medicare, private insurers) covering the procedure, which is not guaranteed.
Unusual Items
- Government Grants: R&D expenses are net of grants from the Office of the Chief Scientist (OCS) and BIRD Foundation. These grants create contingent royalty liabilities based on future revenues.
- Share-Based Compensation: Significant non-cash expense ($312k in 2014) related to stock options and warrants.
Investor Verification Checklist
- Regulatory Milestones: Verify the status of the multi-center clinical feasibility study and the timeline for the FDA pre-submission meeting scheduled for late 2015.
- Cash Runway: Confirm the actual net proceeds received from the February 2015 IPO and private placement to validate the "funding through end of 2016" assertion.
- Grant Obligations: Review the specific terms of the OCS and BIRD Foundation grants to understand the potential future royalty burden (up to 100% of grant value plus interest) if the product generates revenue.
- Supply Chain: Assess the company's contingency plans for single-source suppliers of the X-ray source, motor, and ASIC components.
- Competition: Evaluate the competitive landscape, specifically the market penetration of optical capsule endoscopy (e.g., Given Imaging/Covidien) and stool DNA tests (e.g., Exact Sciences/Cologuard).